2.1 Depressive Symptoms: Aim 2.1.1: To determine the effect of ibogaine treatment on depressive symptomatology as measured by changes in MADRS score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.1.2: To determine the effect of ibogaine treatment on depressive symptomatology as measured by changes in MADRS score from baseline to one-month post treatment in an observational study of individuals with history of TBI. Aim 2.1.3: To determine the effect of ibogaine treatment on depressive symptomatology as measured by changes in PHQ-8 score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.1.4: To determine the effect of ibogaine treatment on depressive symptomatology as measured by changes in PHQ-8 score from baseline to one-month post treatment in an observational study of individuals with history of TBI. 2.2 Anxious symptoms: Aim 2.2.1: To determine the effect of ibogaine treatment on anxious symptomatology as measured by changes in SIGH-A score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.2.2: To determine the effect of ibogaine treatment on anxious symptomatology as measured by changes in SIGH-A score from baseline to one-month post treatment in an observational study of individuals with history of TBI. Aim 2.2.3: To determine the effect of ibogaine treatment on anxious symptomatology as measured by changes in GAD-7 score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.2.4: To determine the effect of ibogaine treatment on anxious symptomatology as measured by changes in GAD-7 score from baseline to one-month post treatment in an observational study of individuals with history of TBI. 2.3 Hopelessness: Aim 2.3.1: To determine the effect of ibogaine treatment on hopelessness as measured by changes in BHS score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.3.2: To determine the effect of ibogaine treatment on hopelessness as measured by changes in BHS score from baseline to one-month post treatment in an observational study of individuals with history of TBI. 2.4 PTSD Symptoms: Aim 2.4.1: To determine the effect of ibogaine treatment on PTSD symptomatology as measured by changes in PCL-5 score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.4.2: To determine the effect of ibogaine treatment on PTSD symptomatology as measured by changes in PCL-5 score from baseline to one-month post treatment in an observational study of individuals with history of TBI. Aim 2.4.3: To determine the effect of ibogaine treatment on PTSD symptomatology as measured by changes in CAPS score from baseline to immediate post treatment in an observational study of individuals with history of TBI. Aim 2.4.4: To determine the effect of ibogaine treatment on PTSD symptomatology as measured by changes in CAPS score from baseline to one-month post treatment in an observational study of individuals with history of TBI. Aim 2.4.5: To determine the effect of ibogaine treatment on PTSD symptomatology as measured by changes in TSI-2 scores from baseline to one-month post treatment in an observational study of individuals with history of TBI. 2.5 Moral Injury: 2.5.1 To determine the effect of ibogaine treatment on moral injury as measured by changes in the Moral Injury Symptoms Scale score from baseline to one-month post treatment in an observational study of individuals with history of TBI. 2.6. Substance Use: Aim 2.6.1: To determine the effect of ibogaine treatment on substance use as measured by changes in the ASI Lite from baseline to one-month post treatment in an observational study of individuals with history of TBI. Aim 2.6.2: To determine the effect of ibogaine treatment on substance use withdrawal as measured by changes in the Substance Use Withdrawal scale from immediate post treatment to one-month post treatment in an observational study of individuals with history of TBI.